Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | DAB2 |
| Gene Name: | DAB2 |
| Protein Full Name: | Disabled homolog 2 |
| Alias: | Differentially expressed protein 2; Differentially-expressed protein 2; Disabled 2; Disabled 2, mitogen-responsive phosphoprotein; DOC2; DOC-2; Mitogen-responsive phosphoprotein |
| Mass (Da): | 82448 |
| Number AA: | 770 |
| UniProt ID: | P98082 |
| Locus ID: | 1601 |
| COSMIC ID: | DAB2 |
| Gene location on chromosome: | 5p13.1 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19806 |
| Percent of cancer specimens with mutations: | 1.01 |
| Gene undergoes hypermethylation: | Yes is nasopharyngeal carcinoma |
| Normal role description: | DAB2 interacts with a variety of proteins in receptor, cell cycle, angiogensis, and vesicle trafficking pathways via PTB and PRB domains. Known targets include SMAD2, RAS/RAF, ERK, SOS, Axin/beta-catenin. Overall effect of these interactions is almost exclusively inhibitory. Thus loss of DAB2 function promotes oncogenesis via upregulation of the above mentioned pathways. |